Tuesday, September 09, 2008 8:12:59 PM
[After the bell.]Sept. 9, 2008
EDISON, N.J. Hanover Capital Mortgage Holdings, Inc. announced today that on September 5, 2008, the American Stock Exchange notified the Company that it had granted the Company an extension until December 31, 2008 to regain compliance with the continued listing standards of Section 1003(a)(iv) of the Amex Company Guide and until October 8, 2009 to regain compliance with the continued listing standards of Section 1003(a)(i) of the Amex Company Guide.
Previously, on April 8, 2008, the Company received notice from the Amex Staff indicating that the Company was below certain of the Exchange's continued listing standards. Specifically, the notice provided that the Company was not in compliance with (1) Section 1003(a)(i) of the Amex Company Guide due to stockholders' equity of less than $2,000,000 and losses from continuing operations and net losses in two out of its three most recent fiscal years, and (2) Section 1003(a)(iv) of the Amex Company Guide in that the Company had sustained losses which were so substantial in relation to overall operations or its existing financial resources, or its financial condition had become so impaired, that it appeared questionable, in the opinion of the Exchange, as to whether the Company would be able to continue operations and/or meet its obligations as they mature.
The Company was afforded the opportunity to submit a plan of compliance and, on May 8, 2008, submitted its plan to the Exchange. The Exchange did not, at that time, accept the Company's plan, and the Company appealed its decision to the Listing Qualifications Panel, with a scheduled hearing date of August 26, 2008. In support of its position, prior to the hearing, the Company submitted to the Exchange certain supplemental materials in advance of such hearing date. Based on those supplemental materials, the Amex notified the Company on August 25 that it was cancelling the hearing and granting the Company an extension to regain compliance with the continued listing standards.
The Company will be subject to periodic review by Exchange Staff during the extension period. Failure to make progress consistent with the plan and to achieve certain milestones, or to regain compliance with the continued listing standards by the end of the extension period could result in the Company's common stock being delisted from the American Stock Exchange.
Hanover Capital Mortgage Holdings, Inc. is a mortgage REIT staffed by seasoned mortgage capital markets professionals. HCM invests in prime mortgage loans and mortgage securities backed by prime mortgage loans.
For further information, visit HCM's Web site at http://www.hanovercapitalholdings.com.
Recent HCM News
- HUTCHMED to Announce 2024 Half-Year Financial Results • GlobeNewswire Inc. • 06/26/2024 08:30:00 AM
- Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024 • GlobeNewswire Inc. • 06/24/2024 09:30:00 AM
- HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda • GlobeNewswire Inc. • 06/21/2024 08:00:00 PM
- HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology • GlobeNewswire Inc. • 06/17/2024 12:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/07/2024 10:25:35 AM
- HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China • GlobeNewswire Inc. • 06/07/2024 12:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 06/03/2024 10:13:17 AM
- HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine • GlobeNewswire Inc. • 06/03/2024 12:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/31/2024 10:12:22 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/24/2024 10:06:58 AM
- HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting • GlobeNewswire Inc. • 05/24/2024 12:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/17/2024 02:02:55 PM
- HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees • GlobeNewswire Inc. • 05/17/2024 02:00:00 PM
- HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress • GlobeNewswire Inc. • 05/17/2024 12:00:00 AM
- HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui • GlobeNewswire Inc. • 05/14/2024 12:00:00 AM
- HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China • GlobeNewswire Inc. • 05/14/2024 12:00:00 AM
- HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee • GlobeNewswire Inc. • 05/08/2024 08:30:00 AM
- HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda • GlobeNewswire Inc. • 04/26/2024 12:30:00 PM
- HUTCHMED Highlights Data to be Presented at AACR Congress 2024 • GlobeNewswire Inc. • 04/05/2024 08:30:00 AM
- HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status • GlobeNewswire Inc. • 04/02/2024 04:30:00 AM
- HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC • GlobeNewswire Inc. • 03/28/2024 12:00:00 AM
- HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China • GlobeNewswire Inc. • 03/22/2024 12:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/05/2024 11:04:49 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/28/2024 11:47:15 AM
- Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/28/2024 11:40:32 AM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM